CJC-1295

Assumed mechanism (class-validated, molecule-specific human data absent): Modified GRF 1-29 is a truncated, enzyme-stabilized analog of growth-hormone-releasing hormone (GHRH). It is assumed to bind the pituitary GHRH receptor on somatotrophs and stimulate synthesis and pulsatile release of the body's own growth hormone, which in turn raises hepatic IGF-1. The four amino-acid substitutions are assumed to slow degradation by DPP-IV and other peptidases, lengthening the active window to ~30 minutes, enough to drive a single GH pulse. Because it acts upstream through the pituitary (rather than being injected GH), the resulting GH rise is assumed to remain under normal somatostatin negative feedback, preserving pulsatility; this is the theoretical safety argument but is unproven for this molecule in humans.

Every human trial of CJC-1295 was done with the DAC form, a different long-acting molecule. The no-DAC product people buy has no human trial. The A tag on the DAC trials is for raising GH and IGF-1 levels only.

Adverse events

Most commonly reported (anecdotal/clinic-level, not from controlled no-DAC trials): injection-site reactions (redness, itching, welts), transient water retention/puffiness, and paresthesia, tingling/numbness in hands and fingers resembling mild carpal-tunnel, a recognized consequence of GH-induced fluid retention compressing the median nerve. Also reported: increased appetite, post-injection flushing/head-rush, lightheadedness, headache, and drowsiness. Effects generally described as mild and settling within the first weeks. None of this is quantified by a controlled human trial of the no-DAC compound. FDA's safety page for CJC-1295 cites increased heart rate and a systemic vasodilatory reaction, and notes limited clinical data.

Contraindications

Should be avoided by anyone with active or recent malignancy (IGF-1 is mitogenic), and used with great caution in diabetes/insulin resistance (GH is diabetogenic). Caution with proliferative diabetic retinopathy and significant cardiovascular disease. Not for pregnancy/breastfeeding or in children/adolescents (open growth plates). The documented phase-II program death in a subject with pre-existing coronary artery disease (DAC version) underscores caution in established cardiac disease, even though the attending physician attributed that death to undiagnosed coronary disease. Gray-market product also carries contamination/mislabeling/dose-accuracy risk independent of the molecule.

Theoretical concerns

Mechanistically, anything that chronically raises GH/IGF-1 carries the theoretical GH-excess risk set: insulin resistance / impaired glucose tolerance, fluid retention and carpal-tunnel-type symptoms, arthralgia, and, with sustained supraphysiologic elevation, a theoretical concern about promoting growth of existing neoplasia (IGF-1 is mitogenic). Because GHRH analogs work through the pituitary, the GH rise is theoretically self-limited by somatostatin feedback (unlike injected rHGH), which is the main argument for a wider margin, but that protective ceiling has not been characterized for this molecule in humans.

What nobody knows yet

The single largest unknown is that there is no completed controlled human trial of the no-DAC molecule, so its actual human dose-response, magnitude and durability of GH/IGF-1 effect, and long-term safety are simply unmeasured. Unknowns include: real-world purity/identity of gray-market vials, chronic-use effects on glucose metabolism and IGF-1 over months-to-years, cancer-risk signal, and whether the assumed pulsatile-GH safety advantage over the DAC version holds in practice. Long-term human safety data: none.

What else could explain the result

Attribution is badly muddied because mod GRF 1-29 is almost never run alone. It is typically stacked with ipamorelin (or another GHRP), so any benefit is a combined GHRH+GHRP effect, not this peptide's. Many users also concurrently run testosterone/TRT, other peptides (BPC-157, tesamorelin), GLP-1 agonists, or are simultaneously dieting and training hard, all of which independently change body composition, recovery and sleep. Improved sleep and 'recovery' are especially confounded by a bedtime routine and expectancy.

Is the vial what it says?

Verified that the human RCT evidence (Teichman, JCEM 2006, PMID 16352683) belongs to CJC-1295 WITH DAC and does not transfer to the no-DAC molecule. Confirmed via PubMed and encyclopedic sources that no controlled human trial of Modified GRF 1-29 itself appears in the literature. Confirmed the structural basis (substitutions at positions 2/8/15/27; ~30-min half-life vs <10 min native; DAC = albumin-binding lysine-maleimide giving the DAC version a ~6-8 day half-life). Confirmed FDA's account of the phase-II trial termination after a subject's death and the withdrawn-nomination status on FDA's 503A lists. Treated all vendor/affiliate pages (peptide sellers, clinic blogs) as non-evidentiary and used them only for community-sentiment and handling conventions, not efficacy claims.

Half-life and storage

Half-life: Approximately 30 minutes (vs under ~10 minutes for native GRF 1-29/sermorelin). This is the defining contrast with CJC-1295 WITH DAC, whose albumin-binding lysine-maleimide complex extends its half-life to roughly 6-8 days.

Once mixed: Supplied as a lyophilized powder, reasonably stable at room temperature while sealed and dry; should be kept away from light, heat and moisture. Reconstitute gently with bacteriostatic water (aim the stream down the vial wall, do not shake, swirl), as peptide chains are shear- and heat-sensitive. After reconstitution, refrigerate at 2-8 C, protect from light, and avoid repeated warming/cooling (temperature cycling) and freezing of the reconstituted solution; reconstituted product is commonly cited as usable for roughly up to ~30 days. Degraded/cloudy or discolored solution should be discarded. Sloppy handling is a real source of lost potency and is often mistaken for a 'non-responder' outcome.

What people report

Volume of reports: moderate. A real body of reports, fairly consistent.

High chatter volume. CJC-1295 (typically the no-DAC + ipamorelin combo) is one of the most widely discussed 'GH peptide' stacks across bodybuilding forums, peptide communities, anti-aging clinics and biohacking content, far more discussion than data. However, the volume is inflated by the ubiquity of vendor and clinic content and by the fact that reports almost never isolate the no-DAC molecule from its ipamorelin partner.

Moderately consistent on the basics: users commonly report better/deeper sleep, improved recovery and a gradual recomposition (slightly leaner, fuller muscle) over weeks-to-months, plus the recognizable side-effect cluster (water retention, hand tingling, head-rush, hunger). Consistency drops on magnitude, claims range from 'subtle, mostly sleep' to dramatic, with the dramatic accounts heavily confounded by concurrent TRT, diet and other compounds. The side-effect pattern is more reliably reported than the benefit.

Low-to-moderate source credibility. A large share of available content is vendor or clinic marketing with an obvious commercial interest, which is discounted. The more credible signal comes from independent forum users describing both upsides and downsides, but these are uncontrolled, unverified-product, polypharmacy anecdotes. Net: enough believable real-world reporting to register as Moderate, but nothing here approaches proof, and the science behind it remains animal-grade.

• (Anecdote, not proof) The most consistent report is improved sleep depth and recovery within the first couple of weeks, though this is exactly where placebo/expectancy and the calming injection ritual are strongest.
• (Anecdote) Body-composition change is described as gradual and subtle over 8-12+ weeks (a bit leaner, fuller muscles) rather than dramatic, and is almost always reported alongside an ipamorelin stack, training and diet, so attribution to this peptide alone is weak.
• (Anecdote) The side-effect cluster is reported reliably: transient water retention/puffiness, tingling or numb fingers (carpal-tunnel-like), a warm flush or light-headed 'head-rush' shortly after injection, and increased hunger, usually described as mild and fading after the first weeks.
• (Anecdote) A recurring community theme is variability and skepticism: some users feel little to nothing, suspect under-dosed or degraded gray-market product, and debate the dosing and fasted-timing rules as folklore, reflecting how much of the practice rests on convention rather than data.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: No controlled human trial of the no-DAC compound (Modified GRF 1-29) has been completed or published. The molecule was first characterized as a "long-lasting GRF analog" in research around 2005. The widely cited human RCT (Teichman et al., JCEM 2006) studied CJC-1295 WITH DAC, a structurally different long-acting molecule, not this one. Human exposure to the no-DAC version is essentially limited to off-label clinic use and self-experimentation in the gray market from roughly the early-2010s onward; none of it is documented in controlled trials.

1. 1982-1983Native GRF/GHRH (1-44 and 1-29 fragments) characterized; GRF(1-29) ('sermorelin') established as the minimal active sequence that stimulates pituitary GH.
2. 1990sSermorelin (Geref) reaches the market as an FDA-approved GHRH analog for GH-deficiency diagnosis/treatment, establishing the human GHRH-analog pathway. (Later discontinued commercially.)
3. ~2005Tetrasubstituted Modified GRF (1-29), the no-DAC molecule, characterized as a 'long-lasting GRF analog,' with substitutions at positions 2, 8, 15 and 27 to resist enzymatic degradation (half-life extended to ~30 min).
4. 2006Teichman et al. publish the human RCT of CJC-1295 WITH DAC (the albumin-binding, multi-day variant) in JCEM, the data most often (mis)cited for the no-DAC version.
5. Late 2000sCJC-1295 (DAC) clinical development for lipodystrophy/GH deficiency reaches phase II, then is discontinued after a trial subject's death (attributed by the attending physician to undiagnosed coronary artery disease).
6. ~2010s onwardNo-DAC mod GRF 1-29 proliferates in the gray-market 'research peptide' channel, typically paired with ipamorelin; no controlled human trials of the no-DAC molecule are conducted.
7. 2024FDA removes CJC-1295 from Category 2 of the interim 503A bulks list after the nominator withdraws it; FDA does not add it to Category 1. Leaves it unapproved and outside permitted compounding.
8. Dec 2024FDA's advisory committee votes against adding CJC-1295 to the 503A bulks list (free base 0 yes to 13 no; acetate 1 to 12; DAC forms 0 to 13).

• Teichman et al., JCEM 2006. CJC-1295 (DAC) human RCT (PMID 16352683)(The pivotal human trial, but of the DAC version, NOT the no-DAC molecule. Most-cited and most-misapplied source for mod GRF 1-29.)
• PubMed search. Modified GRF (1-29) / CJC-1295 without DAC(Run this to see for yourself: no controlled human trial of the no-DAC compound surfaces. The empty result is the headline.)
• Ionescu and Frohman, JCEM 2006: pulsatile GH persists during continuous CJC-1295 stimulation (PMID 17018654)(Human data on the DAC form showing GH pulsatility persists under continuous GHRH-analog stimulation (class plausibility).)
• Jette et al., Endocrinology 2005, hGRF(1-29)-albumin bioconjugates / CJC-1295 in rats (PMID 15817669)(Rat pharmacology of the CJC-1295 family; animal-grade only.)
• ClinicalTrials.gov. CJC-1295 trial record search(Context for the discontinued DAC development program (phase II halt after a subject death attributed by the attending physician to coronary artery disease).)
• FDA. Bulk Drug Substances for Compounding under 503A(Regulatory status: CJC-1295 not approved, no USP/NF monograph; Category 2 listing ended after the nominator withdrew, not on any current 503A category list.)
• FDA final summary minutes, PCAC Dec 4, 2024(Advisory committee voted against listing CJC-1295 for 503A: free base 0 to 13, acetate 1 to 12, DAC forms 0 to 13.)
• FDA. Certain Bulk Drug Substances That May Present Significant Safety Risks(Background on the Category 2 'significant safety risk' designation that applied to compounded peptides like CJC-1295.)
• Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis. Front Endocrinol 17:1822475 (2026), Table 2, row CJC-1295 (without DAC), footnote **(dose table)
• Teichman SL, et al. J Clin Endocrinol Metab 2006;91(3):799-805. doi:10.1210/jc.2005-1536(dose table)
• Ionescu M, Frohman LA. J Clin Endocrinol Metab 2006;91(12):4792-7. doi:10.1210/jc.2006-1702(dose table)
• The Peter Attia Drive #387, AMA #83: Peptides, show notes sections "Peptide case study: CJC-1295" and "CJC-1295 continued" (April 2026)(dose table)
• Huberman Lab, April 1, 2024, chapter Secretagogues, Sermorelin, Tesamorelin, CJC-1295(dose table)
• Huberman Lab, Dr. Craig Koniver, chapter Tesamorelin, Sermorelin, CJC-1295, released Oct 2024(dose table)